Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2004-12-14
2011-10-04
Saunders, David A (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S001210, C424S450000, C424S489000, C424S490000, C424S172100, C424S178100
Reexamination Certificate
active
08029795
ABSTRACT:
A targeted iron chelator delivery system that comprises an iron chelator, a targeting agent and a lipid carrier, e.g., a liposome, is provided. The iron chelator delivery system may be used to remove excess iron from specific organs such as, for example, heart and liver tissue. Methods for preparing and administering the targeted iron chelator delivery system are also provided. The iron chelator delivery system may be administered during a blood transfusion to prevent iron overload.
REFERENCES:
patent: 4397867 (1983-08-01), Blake
patent: 6056938 (2000-05-01), Unger et al.
patent: 7494666 (2009-02-01), McDonald et al.
patent: 2001/0048914 (2001-12-01), Larsen et al.
patent: 2002/0028474 (2002-03-01), Shibamura et al.
patent: WO 01/49266 (2001-07-01), None
patent: WO 2004/002455 (2004-01-01), None
Wu et al., “The prospects of hepatic drug delivery and gene therapy,”Expert Opin Investig Drugs, 7(11), pp. 1795-1817, 1998.
Nag et al., “Assessment of targeting potential of galactosylated and mannosylated sterically stabilized liposomes to different cell types of mouse liver,”J. Drug Target, 6(6), pp. 427-438, 1999.
Klibanov et al., “Targeting of macromolecular carriers and liposomes by antibodies to myosin heavy chain,”Am. J. Physiol., 261(4) Suppl.,pp. 60-65, 1991.
Torchillin et al., “Preservation of antimyosin antibody activity after covalent coupling to liposomes,” Biochem. Biophys. Res. Commun. 89(4), 1114-1119, 1979.
Dufresne et al., “Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab' fragments,” Biochim. Biophys. Acta, 1421(2), 284-294, 1999.
Maruyama et al., “Lipid composition is important for highly efficient target binding and retention of immunoliposomes,” Proc. Nat'l. Acad. Sci., USA, 87:5744-5748, 1990.
Maruyama et al., “Possibility of active targeting to tumor tissues with liposomes,” Adv. Drug. Deliv. Rev., 40 (1-2), 89-102, 1999.
Vingerhoeds et al., “Immunoliposomes in Vivo,” Immunomethods, 4(3), 259-272, 1994.
Hopkins, S.J. et al., “Liposome-Entrapped Desferrioxamine,”Drugs of the Future, vol. 4, No. 7, pp. 500-506 (1979).
Lau, E.H. et al., Improvement of iron removal from reticuloendothelial system by liposome encapsulation of N,N′-bis[2-hydroxy-benzyl]-ethylenediamine-N,N′-diacetic adic (HBED),J. Laboratory and Clinical Medicine, vol. 101, No. 5, pp. 806-816 (1983).
Lau, E.H. et al., “Liposome-encapsulated Desferrioxamine in Experimental Iron Overload,”British J. of Haematology, vol. 47, pp. 505-518 (1981).
Postma, N.S. et al., “Absorption and biodistribuion of111indium-labelled desferrioxamine (111In-DFO) after subcutaneous injection of111In-DFO liposomes,”J. of Controlled Release, vol. 58, pp. 51-60 (1999).
Rahman, Y.E., “Liposomes as Delivery Systems for Iron Chelators,”Devel. Of Iron Chelators for Clinical Use, Proc. Symp., 2nd, pp. 211-225 (1980).
Rahman, Y.E. et al., “Application of Liposomes to Metal Chelation Therapy,”Liposomes and Immunobiology, Proc. Nat'l Symp., pp. 285-299 (1980).
Young, S.P. et al., “Liposome Entrapped Desferrioxamine and Iron Transporting Ionophores: a New Approach to Iron Chelation Therapy,”British J. of Haematology, vol. 41, pp. 357-363 (1979).
Leserman et al., “Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A,” Nature, 288:602-604, 1980.
Caride, V.J., “Liposome Accumulation in Regions of Experimental Myocardial Infarction”, Science, vol. 198, pp. 735-738, Nov. 18, 1977.
Gwathmey, Inc.
Lando & Anastasi LLP
Saunders David A
LandOfFree
Targeted iron chelator delivery system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeted iron chelator delivery system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted iron chelator delivery system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4262577